What's New in the Biotechnology Sector: Special Research on Vical,Asterias, Bacterin, Hemispherx BioPharma, and IGI Laboratories

NEW YORK, February 19, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including Vical (NASDAQ: VICL), Asterias (NYSEMKT: AST), Bacterin (NYSEMKT: BONE), Hemispherx BioPharma (NYSEMKT: HEB), and IGI Laboratories (NYSEMKT: IG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

VICL Research Report: ( http://get.analystsreview.com/pdf/?c=Vical&d=19-Feb-2015&s=VICL ),

AST Research Report: ( http://get.analystsreview.com/pdf/?c=Asterias&d=19-Feb-2015&s=AST ),

BONE Research Report: ( http://get.analystsreview.com/pdf/?c=Bacterin&d=19-Feb-2015&s=BONE ),

HEB Research Report: ( http://get.analystsreview.com/pdf/?c=Hemispherx%20BioPharma&d=19-Feb-2015&s=HEB ),

IG Research Report: ( http://get.analystsreview.com/pdf/?c=IGI%20Laboratories&d=19-Feb-2015&s=IG ).

============

--

Analyst Update: Collaborations, Quarterly Results, Recognitions, Scheduled Events, and New Discoveries

Reviewed by: Rohit Tuli, CFA®  

The US stock markets mostly closed lower on Wednesday despite progress in Greece negotiations and dovish Fed minutes. Dow Jones Industrial Average closed down 17.85 points, or 0.10%, at 18,029.85; S&P 500 closed down 0.68 points, or 0.03%, at 2,099.66; Nasdaq closed up 7.10 points, or 0.14%, at 4,906.36. European stocks ended mostly higher and rose to seven-year high amid Greek deal prospects, as Greece is expected to submit a loan request on Thursday to extend a loan agreement for up to six months. The FTSEuroFirst 300 index rose 0.7% to a fresh seven-year high of 1,515.90. On the other hand, most Asian stocks advanced on Wednesday due to investor optimism ahead of a European Central Bank meeting on bailout conditions for Greece, though many markets of the region were shut for the Lunar New Year.

Vical Incorporated (Vical) has entered into collaboration with AnGes MG to develop and commercialize an equine polyclonal antibody therapy for patients afflicted with Ebola virus disease.

Under the agreement, Vical will develop and provide to AnGes a DNA vaccine encoding the glycoprotein antigen of the 2014 Zaire strain of Ebola virus, formulated with Vical's proprietary Vaxfectin® adjuvant.

Asterias Biotherapeutics, Inc.'s (Asterias) lead clinical program, AST-OPC1 (oligodendrocyte progenitor cells) for complete cervical spinal cord injury (SCI), has been selected as one of ten "Top Advanced Therapies Projects to Watch" by Elsevier Business Intelligence.

Developer, manufacturer and marketer of biologics products to domestic and international markets,

Bacterin International Holdings, Inc. (Bacterin) announced its preliminary Q4 2014 revenue results. The Company expects its revenue for Q4 2014 to be in the range of $8.9 million to $9.1 million, compared to $8.3 million reported for Q4 2013.

Hemispherx BioPharma, Inc. (Hemispherx BioPharma) and the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) have scheduled to present new discoveries concerning the efficacy of Ampligen® (rintatolimod) against the Ebola Virus at the 7th Annual International Symposium on Filoviruses - Ebola: West Africa and Recent Developments in Washington, DC, to be held from March 25-28, 2015.

IGI Laboratories, Inc. (IGI Laboratories) has scheduled its Q4 2014 earnings release on Monday, March 2, 2015; followed by a conference call along with a webcast at 4:15 p.m. ET to discuss its Q4 2014 results. As per Zacks investments research, the Company is expected to report earnings of $0.06 per share, both for Q4 2014 and for full-year 2014.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review